Autism Spectrum Disorder
Conditions
Keywords
human Bone Marrow Mesenchymal Stem Cell (hBMMSC), Autism Spectrum Disorder (ASD)
Brief summary
This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).
Detailed description
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized primarily by impaired social communication, restricted interests, and repetitive, stereotyped behaviors. Currently, there are no effective therapeutic drugs, and main interventions consist of educational rehabilitation and behavioral management.The purpose of this study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with ASD. The clinical trial intends to involve 42 participants. The trial is expected to last approximately 2 years.
Interventions
BIOLOGICALhBMMSC
Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.
Sponsors
Capital Medical University
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female ≥6 years old * Body weight ≥ 17 kg * Meets the diagnostic criteria for Autism Spectrum Disorder (ASD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and confirmed by the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-2 (ADOS-2) * Has either not received any psychotropic medication in the three months prior to enrollment or has been on a stable regimen of psychotropic medication for at least three months * The subject and/or their legal guardian(s) agree to participate in the trial and provide signed informed consent.
Exclusion criteria
* Inability of the subject or their guardian to sufficiently understand instructions in Chinese * Active infection (viral, bacterial, fungal, or mycobacterial) * A confirmed diagnosis of Rett syndrome, childhood disintegrative disorder, fragile X syndrome, or other genetic/metabolic diseases that may impact cognitive development * History of epileptic seizures within 6 months prior to enrollment * History of suicide attempts/self-harm, presentation of suicidal ideation, or being judged as the risk of suicidal by the investigator * Severe hematologic diseases or active malignancy * Severe hepatic or renal disease * Participation in a drug clinical trial within 3 months prior to enrollment (unless beyond the protocol-defined wash-out period) or participation in any other stem cell study within the past year * A positive skin test result * Any other condition which, in the opinion of the investigator, would make the subject unsuitable for participation in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety Evaluation of hBMMSC Injection in ASD Patients | 48 weeks | Adverse events and serious adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Preliminary Efficacy Evaluation of hBMMSC Injection for Patients with ASD | 48 weeks | Changes in the scores of the Adaptive Behavior Assessment System (ABAS), Autism Behavior Checklist (ABC), Clinical Global Impression (CGI), Autism Treatment Evaluation Checklist (ATEC), Social Responsiveness Scale(SRS), Repetitive Behavior Scale-Revised (RBS-R), as well as the levels of blood inflammatory factors. |
Contacts
Primary Contactyuan chen
Outcome results
None listed